Top Stories
The GLIP-1/GIP dual agonist was approved to lower the risk of major adverse cardiovascular events in patients with type 2 diabetes.
The stalking-horse bid, which includes an upfront payment of $57.5 million, would give Teva worldwide rights to assets including agitation treatment Igalmi.
A data safety monitoring board found there was a "numerical imbalance" in overall survival between patients receiving autogene cevumeran and those who did not.
The concern appears to be whether TTR-silencing drugs like eplontersen provide any meaningful additional benefit for patients who are already on TTR stabilisers.
Cardiac myosin inhibitor Myqorzo demonstrated clinical improvements in exercise capacity, cardiac structure, cardiac biomarkers, diastolic function and symptom burden.
Conference News
ACACIA-HCM is the First Phase 3 Clinical Trial to Successfully Demonstrate Statistically Significant Improvements Across Both Patient-Reported and Physician-Assessed Endpoints in Non-Obstructive HCMSu...
ADVANCE OUTCOMES presentations include an analysis showing that ralinepag achieved clinical improvement in a lower risk pulmonary arterial hypertension (PAH) population and reduced clinical worsening ...
Detailed ACACIA-HCM data shared at the ESC Congress reinforce Cytokinetics' plans to establish Myqorzo as a first-to-market leader in non-obstructive hypertrophic cardiomyopathy.
Analyses from the multinational MILOS study show that LDL-C reductions achieved after up to one year of treatment with bempedoic acid result in a relative reduction of 17.1% and an absolute reduction ...
-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026--Phase 1a clinical data for CTX310® continued to demonstrate robust, dose-dependent reductions...
